Saol Therapeutics Announces Major Clinical Milestones Across Multiple Development Programs
Hand-out
Press Releases
April 18, 2025

Saol Therapeutics Announces Major Clinical Milestones Across Multiple Development Programs

SL1009 targets a 2025 FDA decision for Pyruvate Dehydrogenase Complex Deficiency (PDCD), while SL1002 advances toward Phase III trials for osteoarthritis knee pain and spasticity

bradford

The Bradford Era

More by this Author
Local & Social